Rapid testing manufacturer BioSure was one of 205 organisations nationally recognised with the Queen’s Award for Enterprise earlier this year, with the firm recognised for excellence in innovation.
Based in Essex, BioSure develop, manufacture, source and distribute rapid tests with the highest levels of accuracy.
Its HIV Self Test, which launched in 2015 as the world’s first approved blood-based HIV self-test, was central to this latest recognition, with each drop only requiring a fraction of a drop of blood.
Each test takes 15 minutes and has been proven to deliver very accurate results.
This Queen's Award for Enterprise came in the innovation category, with BioSure actively delivering on its company mission to play a role in ending the global HIV/AIDS epidemic.
BioSure wants to change the conversation surrounding HIV and help people to take control of their HIV status.
BioSure has collaborated with other UK diagnostic manufacturers throughout the COVID-19 pandemic in order to launch a range of COVID-19 tests.
The BioSure COVID-19 IgG Antibody Self Test allows people to know if they have developed neutralising antibodies to the virus.
Brigette Bard, CEO of BioSure, said: “It is a true honour to be recognised for the prestigious Queen’s Award for Enterprise, especially following the challenges of the past year.
As a company we are passionate about self-testing and believe it will change the dynamic of healthcare, taking the strain from overwhelmed healthcare services. Self-testing provides people with a choice, which is critical for getting more people to test, plus it offers an incredibly cost-effective solution.
Our success has been built on our consumer responsive approach – everything we do is designed and refined with the unique needs of our customers in mind”.